Glycosaminoglycan oral use and compositions
The present invention concerns the use of a glycosaminoglycan association of hyaluronic acid and chondroitin sulfate for the preparation of oral compositions for the prevention or for the treatment of upper gastro-intestinal tract disorders and for the preparation of upper gastro-intestinal epithelial damage, as well as the oral compositions comprising said glycosaminoglycan association.
1. A glycosaminoglycan oral composition in unit dosage form comprising
(a) from 80 mg to 200 mg of hyaluronic acid or a pharmaceutically acceptable salt thereof having an average molecular weight of not less than 10 5 Da; and
(b) from 150 mg to 500 mg of chondroitin sulfate or a pharmaceutically acceptable salt thereof having an average molecular weight of from 5,000 to 50,000 Da;
in admixture with a pharmaceutical carrier, said composition being formulated in a formulation wherein active ingredients are mixed with a poloxamer as a bioadhesive agent which is capable to adhere to the esophagus wall together with said active ingredients.
2. The composition according to claim 1 , having a viscosity of from 30 to 100 mPa.
3. The composition according to claim 1 , having a pH of from 4 to 6.
4. The composition according to claim 1 , wherein said hyaluronic acid has an average molecular weight of from 10 5 to 10 6 Da, said chondroitin sulfate has an average molecular weight of from 12,000 to 50,000 Da and pH is of from 4.8 to 5.2.
5. The composition according to claim 1 , wherein both hyaluronic acid and chondroitin sulfate are purified products.
6. The composition according to claim 1 , which is practically protein-free.
7. The composition according to claim 1 , wherein both hyaluronic acid and chondroitin sulfate are in form of their sodium or potassium salts.
8. A method for treatment of esophagitis in human which comprises administering to said human a glycosaminoglycan oral composition comprising
(a) from 80 mg to 200 mg of hyaluronic acid or a pharmaceutically acceptable salt thereof having an average molecular weight of not less than 10 5 Da; and
(b) from 150 mg to 500 mg of chondroitin sulfate or a pharmaceutically acceptable salt thereof having an average molecular weight of from 5,000 to 50,000 Da;
in admixture with a pharmaceutical carrier, said composition being formulated in a formulation wherein active ingredients are mixed with a poloxamer as a bioadhesive agent which is capable to adhere to the esophagus wall together with said active ingredients.
9. The method of claim 8 , wherein both hyaluronic acid and condroitin sulfate are in form of their sodium or potassium salts.
10. The method of claim 8 , wherein esophagitis is due to hyperacidity or to adverse effects of drugs.
11. The method of claim 8 , wherein said oral composition is a liquid oral composition.